The DEEP project has received research funding from the European Union under the 7th Framework Programme

Apotex Inc.

Apotex is a wholly owned subsidiary of Apotex Holdings Inc. and is sister company of Apopharma. Apotex is a fully integrated pharmaceutical company, devoted primarily to generic drug development and manufacturing and including facilities for fine chemical manufacturing and clinical testing (Phase I), primarily for bioavailability studies. Apotex has developed more than a thousand different drug formulations for more than 300 different molecules and has registrations in more than 100 countries around the world.

Main tasks in the project 

Apotex is involved in WP2, to:

– Establish container closure
– Develop specifications
– Plan a stability program
– Prepare manufacture batches
– Develop a new oral solution formulation of deferiprone suitable for paediatric use

Signet Drive 150
M9L 1T9 Toronto – Canada